Dextromethorphan and guaifenesin use needs to be monitored cautiously in clients with "weak metabolizer" CYP2D6 enzyme levels and patients that are sedated. This combination medication includes a substantial median toxic dose (TD50) to median successful dose (ED50) ratio (or therapeutic index) in these people. Delsym has a full line of https://olivebookmarks.com/story18286660/details-fiction-and-dextromethorphan-dxm-for-sale-in-copyright